IQVIA

IQV

Market cap $31.7B

Overview Fund Activity

186.69 USD

-0.12

0.06%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

187.69

+1.00

0.54%

1 day

-0.06%

5 days

1.13%

1 month

-3.04%

3 months

21.15%

6 months

0.97%

Year to date

-4.32%

1 year

-22.21%

5 years

16.32%

10 years

138%

About: Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

Employees: 90,000

Healthcare Diagnostics & Research

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

76% more call options, than puts

Call options by funds: $460M | Put options by funds: $262M

31% more repeat investments, than reductions

Existing positions increased: 419 | Existing positions reduced: 320

7.41% more ownership

Funds ownership: 86.53% [Q1] → 93.94% (+7.41%) [Q2]

0% more first-time investments, than exits

New positions opened: 123 | Existing positions closed: 123

5% less capital invested

Capital invested by funds: $26.8B [Q1] → $25.5B (-$1.32B) [Q2]

1% less funds holding

Funds holding: 977 [Q1] → 964 (-13) [Q2]

17% less funds holding in top 10

Funds holding in top 10: 12 [Q1] → 10 (-2) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$180

4% downside

Avg. target

$210

13% upside

High target

$235

26% upside

7 analyst ratings

5 positive

71%

2 neutral

29%

0 negative

0%

Jefferies David Windley	$225	Buy Upgraded	9 Sep 2025
Mizuho Ann Hynes	$225	Outperform Maintained	25 Jul 2025
UBS Dan Leonard	$225	Buy Maintained	23 Jul 2025
Truist Securities Jailendra Singh	$235	Buy Maintained	23 Jul 2025
Barclays Luke Sergott	$185	Equal-Weight Maintained	23 Jul 2025
Baird Eric Coldwell	$196	Neutral Maintained	23 Jul 2025
Evercore ISI Group Elizabeth Anderson	$180	Outperform Maintained	9 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about IQV published over the past 30 days

IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been honored with the WCG Pinnacle Award for Site Relationships in Professionalism and Communication. The award recognizes IQVIA's commitment to building strong, collaborative partnerships with clinical trial sites worldwide. The award is based on feedback from over 12,000 par.

IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships

IQVIA: A Positive Long-Term Outlook Despite Trump Legislation

Companies and institutions continue to conduct clinical trials, indicating that the CRO market demand will continue to grow. The revenues of the TAS segment increased by 7.67% in the first half of 2025 compared to the same period of 2024, indicating the excellent performance of this segment. IQVIA's book-to-bill ratio has declined to 1.1 in Q2 2025, its lowest level since at least 2019. This ratio should increase if the macroeconomic uncertainty disappears.

IQVIA: A Positive Long-Term Outlook Despite Trump Legislation

IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-enabled platform orchestrating all financial aspects of clinical trials. CTFS is designed to eliminate inefficiencies created by siloed systems and fragmented processes. In contrast to other industry of.

IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management

Zacks Investment Research

Here's Why IQVIA Holdings (IQV) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why IQVIA Holdings (IQV) is a Strong Value Stock

IQVIA names Michael Fedock as financial chief

IQVIA Holdings on Tuesday named insider Michael Fedock as Chief Financial Officer, effective February 28, 2026, succeeding Ron Bruehlman who is set to retire.

IQVIA names Michael Fedock as financial chief

IQVIA Announces CFO Transition in Early 2026

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries, today announced a planned leadership transition in its finance organization. Michael Fedock, currently Senior Vice President of Financial Planning & Analysis, has been appointed Executive Vice President and Chief Financial Officer, effective February 28, 2.

IQVIA Announces CFO Transition in Early 2026

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass.

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

The Big 3: BLDR, IQV, LOW

Jessica Inskip expects Jackson Hole this week to be a big market mover. She also sees a potential path for interest rates during the meeting adding momentum to the homebuilder space, including Builders FirstSource (BLDR).

The Big 3: BLDR, IQV, LOW

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

Global partnerships to help customers improve clinical and commercial efficiency and effectiveness RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif.

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

RESEARCH TRIANGLE PARK, N.C. & PLEASANTON, Calif.--(BUSINESS WIRE)--IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data, technology, and service offerings from Veeva and IQVIA together in a simple and efficient way. The global partnerships make it easy for customers to work with IQVIA and Veeva in key are.

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

See News Rankings

Charts implemented using Lightweight Charts™